Bulk Price D-Alpha-Cyclohexylglycine Manufacturer 2026: Strategic Sourcing Guide
Executive Summary:
- Chemical Kinetics: Optimized resolution routes ensure >99% ee for complex peptide coupling.
- Logistics Stability: Factory-direct shipping models reduce lead times and mitigate supply chain bottlenecks.
- Cost Efficiency: Tiered pricing structures for tonnage quantities significantly lower unit costs versus catalog rates.
As the pharmaceutical landscape shifts towards 2026, procurement strategies for chiral building blocks are evolving from simple catalog purchasing to strategic contract manufacturing. For process development teams and supply chain directors, understanding the bulk price dynamics of D-Cyclohexylglycine (CAS: 14328-52-0) is critical for maintaining margin integrity in peptide drug production. This analysis details the technical and commercial factors influencing cost structures for this essential chiral intermediate.
Understanding Bulk Pricing Tiers Versus Catalog Rates
Market data indicates a significant divergence between gram-scale catalog pricing and metric-ton contract manufacturing rates. Distributors often apply substantial markups to cover storage, handling, and fragmented logistics. In contrast, engaging directly with a primary manufacturer allows for cost optimization based on volume commitments. For projects requiring industrial purity at scale, the price per kilogram can decrease by up to 60% when moving from laboratory packs to drum quantities.
Procurement officers must evaluate the total cost of ownership, which includes quality verification and supply continuity. When sourcing high-purity D-alpha-Cyclohexylglycine, buyers should prioritize suppliers who offer transparent cost breakdowns linked to synthesis complexity rather than simple market speculation. Factory-direct engagement eliminates intermediary fees, ensuring that budget allocation supports actual production capacity rather than distribution overhead.
Technical Synthesis and Purity Profiles
For R&D leads and process chemists, the synthetic route dictates both the cost and the impurity profile of the final active pharmaceutical ingredient (API) precursor. The production of (2R)-2-Amino-2-cyclohexylacetic acid typically involves enzymatic resolution or asymmetric hydrogenation. High-efficiency routes aim for minimal solvent usage and maximal recovery rates to maintain commercial viability.
Key technical parameters influencing bulk price include:
- Enantiomeric Excess (ee): Pharmaceutical grade specifications often require >99.0% ee to prevent downstream diastereomer formation during peptide synthesis.
- Residual Solvents: Compliance with ICH Q3C guidelines is mandatory for commercial batches.
- Heavy Metals: Strict limits are enforced to meet global regulatory standards for parenteral applications.
Manufacturers utilizing advanced crystallization techniques can achieve process-scale purity without extensive chromatographic purification, which significantly reduces production costs. This technical efficiency is passed down to the buyer in the form of competitive pricing for large-scale orders.
Global Manufacturer Supply Chain and Logistics
Supply chain resilience is a primary concern for executives planning long-term production cycles. Reliance on single-source distributors can introduce vulnerability regarding stock levels and lead times. A robust manufacturing partner maintains safety stock and offers flexible packaging solutions ranging from kilograms to tons.
NINGBO INNO PHARMCHEM CO.,LTD. operates as a premier global manufacturer offering these technical advantages and bulk supply capabilities. By controlling the synthesis from raw material sourcing to final packaging, we ensure batch-to-batch consistency and reliable delivery schedules. This vertical integration is crucial for mitigating the risks associated with geopolitical shifts or raw material shortages that often plague fragmented supply networks.
Quality Parameters and Specifications
The following table outlines the standard technical specifications expected for commercial grade procurement in 2026.
| Parameter | Specification | Testing Method |
|---|---|---|
| CAS Number | 14328-52-0 | N/A |
| Chemical Name | D-alpha-Cyclohexylglycine | N/A |
| Purity (HPLC) | >98.5% (Commercial), >99.0% (Pharma) | Area Normalization |
| Enantiomeric Excess | >99.0% ee | Chiral HPLC / GC |
| Appearance | White to Off-White Crystalline Powder | Visual |
| Storage Conditions | Sealed, Dry, 2-8°C or Ambient | N/A |
Requesting Custom Quotes for Large Scale Procurement
Securing favorable terms for 2026 production requires early engagement with manufacturing partners. Standard catalog pricing rarely reflects the realities of tonnage procurement. Executives should initiate discussions regarding volume forecasts and delivery milestones to lock in rates before market fluctuations occur.
To ensure your project meets all technical and regulatory requirements, we invite you to contact our technical sales team for a batch-specific COA, SDS, or bulk pricing quote. Partnering with NINGBO INNO PHARMCHEM CO.,LTD. ensures access to a stable supply of critical building blocks, supporting your transition from clinical trials to commercial manufacturing with confidence.